ABSTRACT: Bladder cancer represents a widespread malignant neoplasm globally, characterized by a notable rate of recurrence following the initial diagnosis and treatment. Traditional methods for ...

AIxMed, an innovator in AI diagnostics for urine cytology and Lumea, a leading provider of primary clinical digital pathology solutions, announced a new partnership. This collaboration will integrate ...

Lumea and AIxMed team up to bring AI driven urine cytology to Lumea's platform, targeting improved bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, an innovator in ...

Lumea will integrate AIxURO into its established digital pathology ecosystem, which is utilized by a significant portion of the U.S. urology market. The addition of this urine cytology AI further ...

Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.

A RECENT multicentre study has demonstrated that a urinary DNA methylation test offers high accuracy in diagnosing high-grade or invasive bladder cancer. Conducted across 10 sites in the Republic of ...

Dr. Aleksic graduated summa cum laude from the University at Buffalo and went on to complete medical school at SUNY Upstate Medical University. Dr. Aleksic received his urological surgery training at ...

TUSTIN, Calif., Dec. 20, 2023 /PRNewswire/ -- Pangea Laboratory has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its non-invasive Bladder CARE™ Assay, ...

Noninvasive Genomic Urine Test Demonstrates High Accuracy in Predicting Recurrence Before Clinical Signs or Symptoms Emerge SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ -- UroAmp, the ...